Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

Panelists discuss how non–muscle-invasive bladder cancer (NMIBC) is staged, graded, and treated according to risk stratification, with detailed explanations of low-, intermediate-, and high-risk ...

Paul E. Dato, MD, discusses how the presence of a BRCA mutation can influence treatment selection and sequencing, supporting consideration of upfront triplet therapy intensification and planning for ...

Panelists discuss how maintenance BCG therapy and vigilant surveillance are essential for sustaining disease control in NMIBC patients, with treatment schedules and monitoring tailored to individual ...

Nearly 60% of patients taking vibegron remained on treatment at 1 year. The real-world, phase 4 COMPOSUR study (NCT05067478) found that nearly 60% of patients taking vibegron remained on treatment at ...

LithoVue Elite's real-time IRP monitoring may expand ureteroscopy to larger stones, improving patient outcomes by reducing complications like bleeding and sepsis. Real-time IRP data aids surgical ...

“The key finding is [that] this might be, in itself, a novel risk factor for bladder cancer," says Laura E. Davis, MD. Data presented at the 2025 American Urological Association (AUA) Annual Meeting ...

Paul E. Dato, MD, discusses how formulation and dosing differences between abiraterone options affect absorption and tolerability, with the micronized version potentially providing better compliance ...

Robotic prostate surgery and resource use: When prostate surgery is performed robotically, the patient typically requires a catheter for about 1 week. This leads to increased resource utilization, ...

Panelists discuss how timely identification of BCG-unresponsive NMIBC through defined response criteria enables dynamic risk stratification and guides critical decisions about escalating care to ...

Yōni.Fit significantly reduced SUI events and pad weights compared to a sham device, achieving FDA 510(k) clearance in May 2024. The study showed a 53% responder rate in the Yōni.Fit group versus 23.3 ...

ACOU085 is a novel otoprotective drug candidate for preventing cisplatin-induced hearing loss in testicular cancer patients. The PROHEAR study involves 40 male patients aged 18-45, receiving high-dose ...